HCG Manavata cancer Centre

Nashik, Maharashtra 42202

1 studies enrolling now · 12 studies all time

What they study most

Advanced Breast Cancer, Advanced Solid Tumor, Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Early Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Lymphoma, Medullary Thyroid Cancer, Migraine, Neoplasm Metastasis

Studies at this site

• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Running, not enrolling
• A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy — Running, not enrolling
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer — Running, not enrolling
• Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study — Enrolling by invitation
• A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. — Running, not enrolling
• A Study in Patients With Advanced Breast Cancer — Stopped early
• A Study of Lasmiditan (LY573144) Over Four Migraine Attacks — Completed